uracil has been researched along with Bile Duct Cancer in 13 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to clarify the safety and efficacy of combination chemotherapy of uracil-tegafur (UFT) and doxorubicin (UFD regimen), and to identify the prognostic factors in patients with unresectable advanced biliary tract cancer who received systemic chemotherapy." | 9.14 | A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer. ( Boku, N; Funakoshi, A; Furuse, J; Nagase, M; Ohkawa, S; Okusaka, T; Sato, T; Yamaguchi, T; Yamao, K, 2009) |
| "Standard chemotherapy for advanced biliary tract cancer has not been established." | 6.72 | Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. ( Funakoshi, A; Furuse, J; Horikawa, Y; Ikeda, M; Ishii, H; Mizuno, N; Morizane, C; Nagase, M; Nakachi, K; Okusaka, T; Ueno, H; Yamao, K, 2006) |
| "The purpose of this study was to clarify the safety and efficacy of combination chemotherapy of uracil-tegafur (UFT) and doxorubicin (UFD regimen), and to identify the prognostic factors in patients with unresectable advanced biliary tract cancer who received systemic chemotherapy." | 5.14 | A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer. ( Boku, N; Funakoshi, A; Furuse, J; Nagase, M; Ohkawa, S; Okusaka, T; Sato, T; Yamaguchi, T; Yamao, K, 2009) |
| "Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy." | 4.40 | Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023) |
| "Four patients with gallbladder cancer and two with bile duct cancer were treated with mitomycin C, carboquone, 5-fluorouracil and OK-432 (MQF-OK therapy) plus tegafur (FT) or UFT." | 3.67 | [MQF-FT and MQF-UFT in gallbladder and bile duct cancer]. ( Fukushi, G; Itoh, T; Kimura, M; Kimura, T; Kishibe, T; Saitoh, S; Sakata, Y; Suzuki, H; Tamura, Y; Tsushima, K, 1988) |
| "Intrahepatic cholangiocellular carcinoma after curative surgery was treated with pharmacokinetic modulation chemotherapy (PMC) as adjuvant chemotherapy." | 2.74 | [Effects of pharmacokinetic modulation chemotherapy (PMC) using oral UFT and venous 5-FU infusion as adjuvant chemotherapy for intrahepatic cholangiocellular carcinoma]. ( Fukumori, D; Kamachi, H; Kamiyama, T; Matsushita, M; Nakagawa, T; Nakanishi, K; Tahara, M; Todo, S; Yokoo, H, 2009) |
| "Standard chemotherapy for advanced biliary tract cancer has not been established." | 2.72 | Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. ( Funakoshi, A; Furuse, J; Horikawa, Y; Ikeda, M; Ishii, H; Mizuno, N; Morizane, C; Nagase, M; Nakachi, K; Okusaka, T; Ueno, H; Yamao, K, 2006) |
| "Biliary papillomatosis is rare, and its pathogenic mechanisms are not yet clear." | 1.42 | Volume-reserving Surgery after Photodynamic Therapy for Biliary Papillomatosis: A Case Report. ( Cheong, CO; Kim, HK; Kim, KS; Lim, JH; Park, JS; Park, SW, 2015) |
| "Primary liver cancer with lymph node metastasis was recognized as poor prognosis." | 1.35 | [A case report of combined hepatocellular-cholangiocarcinoma whose lymph node recurrence effectively treated with UFT]. ( Akagi, K; Dono, K; Fujita, J; Hata, T; Hayashi, S; Ikeda, K; Kagawa, Y; Kawanishi, K; Kitada, M; Munakata, K; Shimano, T; Shimizu, J; Takamoto, K; Watanabe, N; Yasumoto, T; Zenitani, M, 2009) |
| "A 72-year-old man with common bile duct cancer was treated by pylorus preserving pancreatoduodenectomy with D3 lymph node dissection and preventive radiotherapy at hepaticojejunostomy." | 1.32 | [A case of liver metastatic recurrence of bile duct cancer completely responding to single drug, UFT, chemotherapy]. ( Hirano, T; Kitahara, K; Magata, S; Matsuyama, S; Miyazaki, K; Mori, M; Shimonishi, T, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Miyata, T | 1 |
| Beppu, T | 1 |
| Imamura, YU | 1 |
| Hayashi, H | 1 |
| Imai, K | 1 |
| Chikamoto, A | 1 |
| Yamashita, YI | 1 |
| Fukubayashi, K | 1 |
| Ishiko, T | 1 |
| Baba, H | 1 |
| Maeda, T | 1 |
| Hashimoto, K | 1 |
| Ishida, T | 1 |
| Yamashita, Y | 2 |
| Saeki, H | 1 |
| Kawanaka, H | 1 |
| Uchiyama, H | 1 |
| Ikeda, T | 1 |
| Tsujitani, S | 1 |
| Maehara, Y | 1 |
| Cheong, CO | 1 |
| Lim, JH | 1 |
| Park, JS | 1 |
| Park, SW | 1 |
| Kim, HK | 1 |
| Kim, KS | 1 |
| Furuse, J | 2 |
| Okusaka, T | 2 |
| Ohkawa, S | 1 |
| Nagase, M | 2 |
| Funakoshi, A | 2 |
| Boku, N | 1 |
| Yamao, K | 2 |
| Yamaguchi, T | 1 |
| Sato, T | 1 |
| Shimizu, J | 1 |
| Hayashi, S | 1 |
| Dono, K | 1 |
| Yasumoto, T | 1 |
| Zenitani, M | 1 |
| Munakata, K | 1 |
| Watanabe, N | 1 |
| Takamoto, K | 1 |
| Kagawa, Y | 1 |
| Hata, T | 1 |
| Kawanishi, K | 1 |
| Ikeda, K | 1 |
| Fujita, J | 1 |
| Akagi, K | 1 |
| Kitada, M | 1 |
| Shimano, T | 1 |
| Yokoo, H | 1 |
| Kamiyama, T | 1 |
| Nakagawa, T | 1 |
| Nakanishi, K | 1 |
| Tahara, M | 1 |
| Fukumori, D | 1 |
| Kamachi, H | 1 |
| Matsushita, M | 1 |
| Todo, S | 1 |
| Matsuyama, S | 1 |
| Kitahara, K | 1 |
| Hirano, T | 1 |
| Magata, S | 1 |
| Shimonishi, T | 1 |
| Mori, M | 1 |
| Miyazaki, K | 1 |
| Ishii, H | 1 |
| Nakachi, K | 1 |
| Ueno, H | 1 |
| Ikeda, M | 1 |
| Morizane, C | 1 |
| Horikawa, Y | 1 |
| Mizuno, N | 1 |
| Yamamoto, S | 1 |
| Hirata, T | 1 |
| Yamagishi, S | 1 |
| Hirano, S | 1 |
| Kutsukata, N | 1 |
| Masuda, S | 1 |
| Hisayoshi, T | 1 |
| Hioki, M | 1 |
| Mani, S | 1 |
| Sciortino, D | 1 |
| Samuels, B | 1 |
| Arrietta, R | 1 |
| Schilsky, RL | 1 |
| Vokes, EE | 1 |
| Benner, S | 1 |
| Uehara, S | 1 |
| Hirano, F | 1 |
| Sakai, N | 1 |
| Honjo, K | 1 |
| Hirayama, A | 1 |
| Moriya, H | 1 |
| Sakata, Y | 1 |
| Fukushi, G | 1 |
| Tsushima, K | 1 |
| Suzuki, H | 1 |
| Kimura, T | 1 |
| Kimura, M | 1 |
| Tamura, Y | 1 |
| Kishibe, T | 1 |
| Saitoh, S | 1 |
| Itoh, T | 1 |
1 review available for uracil and Bile Duct Cancer
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
5 trials available for uracil and Bile Duct Cancer
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
Topics: Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Du | 2009 |
[Effects of pharmacokinetic modulation chemotherapy (PMC) using oral UFT and venous 5-FU infusion as adjuvant chemotherapy for intrahepatic cholangiocellular carcinoma].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 2009 |
Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; | 2006 |
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Female; Gallbladder Neopl | 1999 |
8 other studies available for uracil and Bile Duct Cancer
| Article | Year |
|---|---|
A 12-year Recurrence-free Survival After Multidisciplinary Treatment for a Patient With Combined Hepatocellular-Cholangiocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Chol | 2019 |
Repeat hepatectomy for intrahepatic recurrence of cholangiolocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; | 2013 |
Volume-reserving Surgery after Photodynamic Therapy for Biliary Papillomatosis: A Case Report.
Topics: Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Embolization, Therapeutic; Gam | 2015 |
[A case report of combined hepatocellular-cholangiocarcinoma whose lymph node recurrence effectively treated with UFT].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neo | 2009 |
[A case of liver metastatic recurrence of bile duct cancer completely responding to single drug, UFT, chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bile Duct Neoplasms; Common Bile Duct; Drug Administrat | 2004 |
[A case of far-advanced gastric cancer treated with neoadjuvant combination chemotherapy of UFT, low-dose CDDP and leucovorin, followed by subtotal gastrectomy with curative intent].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemotherapy, Adjuvant; C | 1997 |
[A case of cholangiocarcinoma with marked reduction of tumor after oral administration of UFT].
Topics: Adenoma, Bile Duct; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bile Duct | 1989 |
[MQF-FT and MQF-UFT in gallbladder and bile duct cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Car | 1988 |